Evidence map›Paper›PMID 34480120›Full record

ArticleBone marrow transplantation2021

Outcomes of pediatric patients with therapy-related myeloid neoplasms.

Akshay Sharma, Sujuan Huang, Ying Li, Russell J Brooke, Ibrahim Ahmed, Heather B Allewelt, Persis Amrolia, Alice Bertaina, Neel S Bhatt, Marc B Bierings and 44 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

54 authors at 20 institutions in 5 countries.

Akshay SharmaBone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA. akshay.sharma@stjude.org.ORCID http://orcid.org/0000-0003-3281-2081
Sujuan HuangBiostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Ying LiBone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.
Russell J BrookeBiostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-7115-2990
Ibrahim AhmedPediatric Hematology, Oncology and BMT, Children's Mercy Hospital Kansas City, Kansas City, MO, USA.ORCID http://orcid.org/0000-0001-5525-9798
Heather B AlleweltPediatric Hematology Oncology, AdventHealth for Children, Orlando, FL, USA.
Persis AmroliaDepartment of Bone Marrow Transplant, Great Ormond St Children's Hospital, London, UK.ORCID http://orcid.org/0000-0003-0480-3911
Alice BertainaHematology, Oncology, Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3729-436X
Neel S BhattClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2033-1125
Marc B BieringsStem cell transplantation, Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands.ORCID http://orcid.org/0000-0002-0192-3080
Joshua BiesPediatrics, University of North Carolina, Chapel Hill, NC, USA.
Claire BrissetHemato-immunology Department, Robert Debré Hospital, GHU APHP Nord-Université de Paris, Paris, France.
Jennifer E BrondonPediatric Transplant and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA.
Ann DahlbergClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jean-Hugues DalleHemato-immunology Department, Robert Debré Hospital, GHU APHP Nord-Université de Paris, Paris, France.ORCID http://orcid.org/0000-0002-8406-0793
Hesham EissaBlood and Marrow Transplant and Cellular Therapeutics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA.
Mony FahdHemato-immunology Department, Robert Debré Hospital, GHU APHP Nord-Université de Paris, Paris, France.
Adam GassasDepartment of Haematology and Oncology, Royal Hospital for Children, Bristol, UK.
Nicholas J GloudePediatrics, University of California San Diego, Rady Children's Hospital San Diego, San Diego, CA, USA.
W Scott GoebelPediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA.
Erika S GoeckermanPediatric Transplant and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA.
Katherine HarrisBlood and Marrow Transplantation, Children's National Hospital, Washington, DC, USA.
Richard HoPediatric Hematology, Oncology and BMT, Vanderbilt University Medical Center, Nashville, TN, USA.
Michelle P HudspethPediatric Hematology and Oncology, Medical University of South Carolina, Charleston, SC, USA.
Jeffrey S HuoPediatric Cellular Therapies, Cancer and Blood Disorders, Atrium Health Levine Children's Hospital, Charlotte, NC, USA.ORCID http://orcid.org/0000-0002-0057-9118
David JacobsohnBlood and Marrow Transplantation, Children's National Hospital, Washington, DC, USA.ORCID http://orcid.org/0000-0001-6119-3270
Kimberly A KasowPediatrics, University of North Carolina, Chapel Hill, NC, USA.
Emmanuel KatsanisDepartment of Pediatrics, University of Arizona, Tucson, AZ, USA.ORCID http://orcid.org/0000-0003-1466-6965
Saara KavianyPediatric Hematology, Oncology and BMT, Vanderbilt University Medical Center, Nashville, TN, USA.
Amy K KeatingDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Nancy A KernanDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Yiouli P KtenaPediatric Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Colette R LauhanPediatrics, University of California San Diego, Rady Children's Hospital San Diego, San Diego, CA, USA.
Gerardo López-HernandezBone Marrow Transplant and Cell therapy Department, National Institute of Pediatrics, Ciudad de Mexico, Mexico.ORCID http://orcid.org/0000-0002-2586-9031
Paul L MartinPediatric Transplant and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA.
Kasiani C MyersDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.ORCID http://orcid.org/0000-0002-5528-4405
Swati NaikCenter for Cell and Gene Therapy, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
Alberto Olaya-VargasBone Marrow Transplant and Cell therapy Department, National Institute of Pediatrics, Ciudad de Mexico, Mexico.
Toshihiro OnishiCenter for Cell and Gene Therapy, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0722-9233
Mohamed RadhiPediatric Hematology, Oncology and BMT, Children's Mercy Hospital Kansas City, Kansas City, MO, USA.
Shanti RamachandranOncology, Haematology, Blood and Marrow Transplantation, Child and Adolescent Health Services, Perth Children's Hospital, Nedlands, WA, Australia.
Kristie RamosDepartment of Pediatrics, University of Arizona, Tucson, AZ, USA.
Hemalatha G RangarajanHematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-3371-2920
Philip A RoehrsPediatric Cellular Therapies, Cancer and Blood Disorders, Atrium Health Levine Children's Hospital, Charlotte, NC, USA.
Megan E SampsonDepartment of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Peter J ShawChildren's Hospital at Westmead, Westmead, NSW, Australia.ORCID http://orcid.org/0000-0003-0101-4482
Jodi L SkilesPediatrics, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN, USA.
Katherine SomersHematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH, USA.
Heather J SymonsPediatric Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Marie de TersantHemato-immunology Department, Robert Debré Hospital, GHU APHP Nord-Université de Paris, Paris, France.
Allison N UberPediatric Hematology and Oncology, Medical University of South Carolina, Charleston, SC, USA.
Birgitta VersluysStem cell transplantation, Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands.ORCID http://orcid.org/0000-0002-4283-5503
Cheng ChengBiostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Brandon M TriplettBone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-8220-9980
St. Jude Children's Research Hospital · USUniversité Paris Cité · FRDuke University · USBaylor College of Medicine · USChildren's Mercy Hospital · USChildren's National · USCincinnati Children's Hospital Medical Center · USFred Hutch Cancer Center · USIndiana University Health · USJohns Hopkins University · USLevine Children's Hospital · USMedical University of South Carolina · USNationwide Children's Hospital · USPrincess Máxima Center · NLUniversity of Arizona · USUniversity of California San Diego · USUniversity of North Carolina at Chapel Hill · USVanderbilt University Medical Center · USAdventHealth for Children · USBristol Royal Hospital for Children · GB

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Long-term outcomes after allogeneic hematopoietic cell transplantation (HCT) for therapy-related myeloid neoplasms (tMNs) are dismal. There are few multicenter studies defining prognostic factors in pediatric patients with tMNs. We have accumulated the largest cohort of pediatric patients who have undergone HCT for a tMN to perform a multivariate analysis defining factors predictive of long-term survival. Sixty-eight percent of the 401 patients underwent HCT using a myeloablative conditioning (MAC) regimen, but there were no statistically significant differences in the overall survival (OS), event-free survival (EFS), or cumulative incidence of relapse and non-relapse mortality based on the conditioning intensity. Among the recipients of MAC regimens, 38.4% of deaths were from treatment-related causes, especially acute graft versus host disease (GVHD) and end-organ failure, as compared to only 20.9% of deaths in the reduced-intensity conditioning (RIC) cohort. Exposure to total body irradiation (TBI) during conditioning and experiencing grade III/IV acute GVHD was associated with worse OS. In addition, a diagnosis of therapy-related myelodysplastic syndrome and having a structurally complex karyotype at tMN diagnosis were associated with worse EFS. Reduced-toxicity (but not reduced-intensity) regimens might help to decrease relapse while limiting mortality associated with TBI-based HCT conditioning in pediatric patients with tMNs.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteChildHumansNeoplasm Recurrence, LocalRetrospective StudiesTransplantation Conditioning

Identifiers

PMID34480120
PMCPMC9260859
OpenAlexW3197689522

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.